Portage Provides update on proposed acquisition of SalvaRx
TORONTO, Aug. 28, 2018 /PRNewswire/ - (CSE: PBT.U) (OTC: PTGEF) Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review. Until the meeting materials have been approved by CSE for distribution, however, trading in the shares of Portage will remain halted. Upon clearance of the meeting materials, a further announcement will be made regarding the meeting date and a trade resumption date.
Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company's future plans and operations, including management's assessment of the Company's expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.